SciBase Secures Major US Payer Coverage and Aims for Global Dominance in Skin Assessment #USA #Stockholm #dermatology #Nevisense #SciBase
@newsen.bsky.social
@newsen.bsky.socialSciBase Secures Major US Payer Coverage and Aims for Global Dominance in Skin Assessment #USA #Stockholm #dermatology #Nevisense #SciBase
@newsen.bsky.socialSciBase's EIS Technology Chosen for Groundbreaking NIH Skin Study on Barrier Function #Sweden #Stockholm #Skin_Health #SciBase #EIS_Technology
@newsen.bsky.socialSciBase's Innovative EIS Technology Chosen for NIH Dermatology Study #Sweden #Stockholm #SciBase #NIH_study #EIS_Technology
@newsen.bsky.socialSciBase Achieves Historic Coverage with Highmark, Transforming Dermatology Access #United_States #Stockholm #Nevisense #SciBase #Highmark
@newsen.bsky.socialSciBase Achieves Landmark Payer Coverage with Highmark, Advancing U.S. Expansion #Sweden #Stockholm #Nevisense #SciBase #Highmark
@newsen.bsky.socialSciBase Successfully Registers Rights Issue and Share Conversion in Landmark Decision #Sweden #Stockholm #Nevisense #SciBase #BTA
@newsen.bsky.socialSciBase Adjusts TO 2 Warrants Following Latest Rights Issue Announcement #Sweden #Stockholm #SciBase #Capital_Raise #TO_2_Warrants
@newsen.bsky.socialSciBase Announces Share Issuance for Guarantee Compensation with Bergs Securities #Sweden #Stockholm #SciBase #Rights_Issue #Bergs_Securities
@newsen.bsky.socialSciBase Successfully Completes Rights Issue with Strong Investor Support and $57.5 Million Raised #Sweden #Stockholm #Nevisense #SciBase #Bergs_Securities
@newsen.bsky.socialSciBase Secures Financial Backing for Ongoing Rights Issue Amid Future Investments #Sweden #Stockholm #SciBase #Rights_Issue #Bergs_Securities
@newsen.bsky.socialSciBase Secures Financial Backing Through Guarantee Commitment for Rights Issue #Sweden #Stockholm #SciBase #Rights_Issue #Bergs_Securities
@newsen.bsky.socialSciBase Updates Trading Dates for Subscription Rights and Paid Shares on Nasdaq #Sweden #NASDAQ #Stockholm #SciBase #Rights_Issue
@newsen.bsky.socialSciBase Issues New Information Document for Share Rights Issue, Aims for SEK 58 Million #Sweden #Stockholm #Nevisense #SciBase #Rights_Issue
@newsen.bsky.socialSciBase Strengthens Partnership with Castle Biosciences Through New Order and Clinical Studies #Sweden #Stockholm #SciBase #Castle_Biosciences #Nevisense_Go
@newsen.bsky.socialSciBase Strengthens Collaboration with Castle Biosciences Through Additional Order #Sweden #Stockholm #Nevisense #SciBase #Castle_Biosciences
@newsen.bsky.socialSciBase Strengthens Partnership with Castle Biosciences Through New Order #Sweden #Stockholm #SciBase #Castle_Biosciences #Nevisense_Go
@newsen.bsky.socialSciBase Moves to Strengthen Position with SEK 58 Million Rights Issue Strategy #Sweden #Stockholm #Nevisense #SciBase #Bergs_Securities